ECT2 and ovarian carcinoma: Contrary to this finding, most of the studies reported ECT2 as a marker of bad prognosis in solid malignancies.11,25 Despite many molecular updates for ovarian carcinomas in the literature, still the overall survival of the patients is poor worldwide while it is graves in our part of the world.